

Appendix 3Y

Change of Director's Interest Notice

Name of entity	Impression Healthcare Limited
ACN	93 096 635 246

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Peter WIDDOWS
Date of last notice	26 April 2019

Part 1 - Change of director's relevant interests in securities

Direct or indirect interest	Direct
Nature of indirect interest	n/a
Date of change	23 August 2019
No. and class of securities held prior to change	<ul style="list-style-type: none"> 10,966,666 IHL ordinary shares 3,300,000 IHLOB options 1,833,334 unlisted performance rights
Number and class of securities acquired	1,315,790 IHL Ordinary shares; and 657,895 unlisted \$0.08 Options expiry 30-Sep-21
Number and class of securities disposed	Nil
Value/Consideration	\$50,000
No. of securities held after change	<ul style="list-style-type: none"> 12,282,456 IHL ordinary shares 3,300,000 IHLOB options 1,833,334 unlisted performance rights 657,895 unlisted \$0.08 Options expiry 30-Sep-21
Nature of change	Participation in placement

Part 2 – Change of director's interests in contracts

Not Applicable

Part 3 – Closed period

Were the interests in the securities or contracts detailed above traded during a closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/a
If prior written clearance was provided, on what date was this provided?	N/a

Appendix 3Y

Change of Director's Interest Notice

Name of entity	Impression Healthcare Limited
ACN	93 096 635 246

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Sudhanshu AGARWAL
Date of last notice	29 July 2019

Part 1 - Change of director's relevant interests in securities

Direct or indirect interest	Indirect
Nature of indirect interest	Positions disclosed are held by Cannvalate Pty Ltd. Dr Agarwal is a significant shareholder and director of Cannvalate Pty Ltd
Date of change	23 August 2019
No. and class of securities held prior to change	Nil
Number and class of securities acquired	<ul style="list-style-type: none"> 10,000,000 \$0.02 unlisted options expiry 01-Jan-20 10,000,000 \$0.03 unlisted options expiry 01-May-20
Number and class of securities disposed	Nil
Value/Consideration	Nil
No. of securities held after change	<ul style="list-style-type: none"> 10,000,000 \$0.02 unlisted options expiry 01-Jan-20 10,000,000 \$0.03 unlisted options expiry 01-May-20
Nature of change	Issued upon achievement of hurdles set out in ASX announcement dated 21 March 2019 and approved at shareholder meeting on 9 August 2019

Part 2 – Change of director's interests in contracts

Not Applicable

Part 3 – Closed period

Were the interests in the securities or contracts detailed above traded during a closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/a
If prior written clearance was provided, on what date was this provided?	N/a

Appendix 3Y

Change of Director's Interest Notice

Name of entity	Impression Healthcare Limited
ACN	93 096 635 246

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Joel LATHAM
Date of last notice	29 July 2019

Part 1 - Change of director's relevant interests in securities

Direct or indirect interest	Direct
Nature of indirect interest	n/a
Date of change	23 August 2019
No. and class of securities held prior to change	<ul style="list-style-type: none"> 9,845,795 IHL ordinary shares 4,237,500 IHLOB options 6,000,000 unlisted performance rights
Number and class of securities acquired	400,000 IHL Ordinary shares; and 200,000 unlisted \$0.08 Options expiry 30-Sep-21
Number and class of securities disposed	Nil
Value/Consideration	\$15,200
No. of securities held after change	1) 10,245,795 IHL ordinary shares 2) 4,237,500 IHLOB options 3) 6,000,000 unlisted performance rights 4) 200,000 unlisted \$0.08 Options expiry 30-Sep-21
Nature of change	Participation in placement

Part 2 – Change of director's interests in contracts

Not Applicable

Part 3 – Closed period

Were the interests in the securities or contracts detailed above traded during a closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/a
If prior written clearance was provided, on what date was this provided?	N/a

Appendix 3Y

Change of Director's Interest Notice

Name of entity	Impression Healthcare Limited
ACN	93 096 635 246

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Troy VALENTINE
Date of last notice	30 April 2019

Part 1 - Change of director's relevant interests in securities

Direct or indirect interest	Direct & Indirect
Nature of indirect interest	Refer to notes below
Date of change	23 August 2019
No. and class of securities held prior to change (Refer table 1 in notes below)	<ol style="list-style-type: none"> 1. 19,900,914 listed IHL Ord shares 2. 41,238,607 listed IHLOB options 3. 929,204 unlisted Perf A shares 4. 929,204 unlisted Perf B shares 5. 1,833,334 unlisted Perf Rights
Number and class of securities acquired	7,116,950 unlisted \$0.08 Options expiry 30-Sep-21
Number and class of securities disposed	-929,204 Performance Class A shares - expired
Value/Consideration	Nil
No. of securities held after change	<ol style="list-style-type: none"> 1. 19,900,914 listed IHL Ord shares 2. 41,238,607 listed IHLOB options 3. 7,116,950 unlisted \$0.08 options expiry 30-Sep-21 4. 929,204 unlisted Perf B shares 5. 1,833,334 unlisted Perf rights
Nature of change	Broker options issued from placement

Part 2 – Change of director's interests in contracts

Not Applicable

Part 3 – Closed period

Were the interests in the securities or contracts detailed above traded during a closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/a
If prior written clearance was provided, on what date was this provided?	N/a

Notes – Direct & Indirect Interests

(a) Description of entities/relationships:

Troy Valentine is:

- a beneficiary of the GFCR Investments Trust, the FT Family Trust, and Troy R Valentine Superfund;
- a Director of Tranaj Nominees Pty Ltd, Valplan Pty Ltd, Alignment Capital Pty Ltd and Cityside Pty Ltd;
- 100% shareholder in Cityside Pty Ltd (ACN 112 375 354) (“**Cityside**”)
- 50% shareholder in Alignment Capital Pty Ltd (ACN 167 124 754) (“**Alignment**”)

Ekirtson Nominees Pty Ltd (ACN 137 521 825) is trustee for the GFCR Investments Trust (“**Ekirtson**”)

Tranaj Nominees Pty Ltd (ACN 137 521 843) is trustee of the FT Family Trust (“**Tranaj**”)

Valplan Pty Ltd (ACN 135 296 169) is trustee of the Troy R Valentine Family Superfund (“**Valplan**”)

(b) Table 1 - holdings prior to changes

	IHL	IHLOB	Perf A	Perf B	Perf Rights
Troy Valentine	125,000	-	-	-	-
Ekirtson	625,000	12,426,803	-	-	-
Tranaj	1,766,666	14,036,804	-	-	1,833,334
Valplan	3,000,000	1,500,000	-	-	-
Alignment	11,194,248	12,025,000	929,204	929,204	-
Cityside	3,190,000	1,250,000	-	-	-
	19,900,914	41,238,607	929,204	929,204	1,833,334

(c) Table 2 - holdings after changes

	IHL	IHLOB	Unlisted \$0.08 30-Sep-21 Opts	Perf B	Perf Rights
Troy Valentine	125,000	-	-	-	-
Ekirtson	625,000	12,426,803	-	-	-
Tranaj	1,766,666	14,036,804	7,116,950	-	1,833,334
Valplan	3,000,000	1,500,000	-	-	-
Alignment	11,194,248	12,025,000	-	929,204	-
Cityside	3,190,000	1,250,000	-	-	-
	19,900,914	41,238,607	7,116,950	929,204	1,833,334